Simulations Plus, Inc.

Simulations Plus, Inc. is a healthcare technology company that develops drug discovery and development software for modeling and simulation, and prediction of molecular properties using artificial intelligence and machine learning. Its key products include GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; DDDPlus and MembranePlus simulation products; and ADMET Predictor, a chemistry-based program that predicts molecular properties. The company also offers MonolixSuite products for population analyses and regulatory submissions, as well as consulting services in clinical pharmacology and quantitative systems pharmacology. Its solutions serve pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, along with academic institutions.

Simulations Plus, Inc. is listed on the NasdaqGS exchange under the ticker symbol SLP. Its stock trades in US Dollars (USD). The company is headquartered in the United States and operates primarily in the US region, though its software and services are used globally by clients in the pharmaceutical, biotechnology, and other industries.

Simulations Plus, Inc. operates in the Healthcare sector and is classified under the Health Information Services industry. This means the company provides technology solutions that support healthcare and pharmaceutical research, specifically through software that models drug behavior and predicts molecular properties. Its tools help researchers and companies in drug discovery and development, making it a key player in the health information technology space.

Simulations Plus, Inc. organizes its business into two segments: Software and Services. The Software segment includes products like GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, and MonolixSuite, which are used for modeling and simulation in drug development. The Services segment offers consulting services such as population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing to support regulatory submissions. Additionally, the company provides early drug discovery services and quantitative systems pharmacology consulting.

Simulations Plus, Inc. serves a diverse range of industries including pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic institutions. Its software and consulting services are used globally by researchers and scientists involved in drug discovery and development. The company's tools help these clients predict molecular properties, model drug absorption and distribution, and conduct clinical trial simulations, thereby accelerating the development of new therapies and products.